Every day, scientific innovations occur at the UMCG, University of Groningen and Hanze University as well as at life sciences companies in our region. Innovations that have the potential to evolve to new innovative treatments, but may never reach that stage because the innovator doesn’t know about the possibilities or how to get there.
To support innovators to translate their science into innovative treatment, an initiative was launched offering both financial funding (Pharma Connect Capital) and industrial-style support (Pharma Portal) to scientists who have an idea on developing their innovation towards new pharmaceutical treatments or diagnostic tools.
Sign up via www.campus.groningen.nl/symposium
– Folkert Kuipers, UMCG
– Marian Joëls, UMCG
- Ben Feringa, David Kijlstra (Lumento Therapeutics): Shining light on the development of a new class of cancer therapeutics
- Reinier Schwietert, Marieke Bolling (Philae Pharmaceuticals): Much-needed treatment for Epidermolysis Bullosa (EB)
- Jan Hendriks (Pharma Connect Capital): Financial investment in early stage drug development plans
- Martin Smit (Pharma Portal): Creating feasible plans ready for investment